Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors

摘要

BackgroundImatinib was the first BCR-ABL tyrosine kinase inhibitor (TKI) approved in the United States for the treatment of patients with chronic myelogenous leukemia and is currently the most prescribed TKI. The impending loss of patent exclusivity for imatinib has the potential to reduce costs for payers.